The FDA has approved two anti-BCMA-specific CAR-T cell products, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), for the treatment of relapsed MM. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.